Blurbs Kepler Capital Sticks to Its Buy Rating for Genfit (GNFTF) November 12, 2023 Share FacebookTwitterPinterestWhatsApp Must read Paramount price target raised to $15 from $12 at Wells Fargo December 11, 2023 Nvidia CEO aiming to set up base in Vietnam, Reuters reports December 10, 2023 Utz Brands to host investor day December 10, 2023 Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term... December 10, 2023 Kepler Capital Sticks to Its Buy Rating for Genfit (GNFTF) Source link Share FacebookTwitterPinterestWhatsApp Previous articleKepler Capital Reaffirms Their Buy Rating on Banca Mediolanum SpA (BNMDF)Next articleUnderstanding the Dazzling World of Dividends More articles Universal Music Group (UMGNF) was downgraded to a Hold Rating at Kepler Capital December 10, 2023 Kepler Capital Keeps Their Buy Rating on Genfit (GNFTF) December 10, 2023 Surgery Partners (SGRY): A Solid Buy on Long-Term Growth and Strategic Expansions Despite Near-Term Challenges December 9, 2023 Latest article Paramount price target raised to $15 from $12 at Wells Fargo December 11, 2023 Nvidia CEO aiming to set up base in Vietnam, Reuters reports December 10, 2023 Utz Brands to host investor day December 10, 2023 Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term... December 10, 2023 Jasper Therapeutics Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant in Oral... December 10, 2023